-+ 0.00%
-+ 0.00%
-+ 0.00%

Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3

Benzinga·05/21/2025 14:51:59
Listen to the news
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $6 to $3.